<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>mesothelioma</title>
    <link>/mesothelioma/genepanel/7490/</link>
      <atom:link href="/mesothelioma/genepanel/7490/index.xml" rel="self" type="application/rss+xml" />
    <description>mesothelioma</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png</url>
      <title>mesothelioma</title>
      <link>/mesothelioma/genepanel/7490/</link>
    </image>
    
    <item>
      <title>WT1</title>
      <link>/mesothelioma/genepanel/7490/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/7490/info/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;WT1 transcription factor&lt;/p&gt;
&lt;hr /&gt;
&lt;p align=&#34;left&#34; style=&#34;font-size:16px&#34;&gt;
&lt;p&gt;ENTREZID: &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/gene/7490&#34; target=&#34;_blank&#34;&gt;7490&lt;/a&gt; | Type: Protein Coding |
Map: &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/genome/gdv/browser/gene/?id=7490&#34; target=&#34;_blank&#34;&gt; 11p13&lt;/a&gt;&lt;br&gt;&lt;/p&gt;
OMIM: &lt;a href=&#39;https://omim.org/entry/608978&#39; target=&#39;_blank&#39;&gt;608978&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/607102&#39; target=&#39;_blank&#39;&gt;607102&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/256370&#39; target=&#39;_blank&#39;&gt;256370&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/194080&#39; target=&#39;_blank&#39;&gt;194080&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/194072&#39; target=&#39;_blank&#39;&gt;194072&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/194070&#39; target=&#39;_blank&#39;&gt;194070&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/156240&#39; target=&#39;_blank&#39;&gt;156240&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/136680&#39; target=&#39;_blank&#39;&gt;136680&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/106210&#39; target=&#39;_blank&#39;&gt;106210&lt;/a&gt;
&lt;/p&gt;
&lt;br&gt;
&lt;p align=&#34;justify&#34; style=&#34;font-size:16px&#34;&gt;
&lt;strong&gt;Summary Entrez&lt;/strong&gt; &lt;br&gt;This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation codon upstream of, and in-frame with the first AUG. Authors of &lt;a href=&#34;PMID:7926762&#34; class=&#34;uri&#34;&gt;PMID:7926762&lt;/a&gt; also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated. [provided by RefSeq, Mar 2015] &lt;br&gt;&lt;br&gt;
&lt;/p&gt;
&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>WT1</title>
      <link>/mesothelioma/genepanel/7490/gene_expression/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/7490/gene_expression/</guid>
      <description>
&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p&gt;WT1 transcription factor&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;gene-expression&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Gene Expression&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; WT1 expression overview from &lt;em&gt;human protein atlas database&lt;/em&gt;.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
ENSEMBL
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Tissue
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Protein
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
mRNA
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
breast
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
0.2
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
epididymis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
13.6
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
kidney
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
9.6
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
placenta
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
3.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
prostate
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
0.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
seminal vesicle
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
7.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
soft tissue
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
spleen
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Low
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
21.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ovary
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medium
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
47.0
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
smooth muscle
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medium
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
80.2
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
appendix
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
cervix, uterine
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
9.3
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
endometrium
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
112.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
gallbladder
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
3.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
heart muscle
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.8
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
spleen
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
21.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
testis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not detected
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
55.1
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
breast
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
0.2
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
endometrium
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
112.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
fallopian tube
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
126.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
kidney
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
9.6
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
testis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
55.1
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000184937
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
adipose tissue
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
6.4
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>WT1</title>
      <link>/mesothelioma/genepanel/7490/gene_context/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/7490/gene_context/</guid>
      <description>
&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p&gt;WT1 transcription factor&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;gene-context-sentence&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Gene Context Sentence&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 2.&lt;/strong&gt; Analysis of context sentence of WT1 gene in 42 abstracts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
PMID
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Gene Context Sentence
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/10211120&#34; target=&#34;_blank&#34;&gt;10211120&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Syndecan-1 binds basic fibroblast growth factor (bFGF), modulates neovascularization, plays a role in epithelial differentiation and is up-regulated by WT1. […] This study has analysed syndecan-1 expression in mesothelioma tumours and cell lines by immunohistochemistry and immunoblotting, using anti-syndecan-1 antibody directed against the core protein, and has examined its relation to morphology, bFGF, WT1, and intra-tumoural microvascular density (IMD). […] These studies indicate that (1) there is no correlation of syndecan-1 with either bFGF expression or IMD in mesotheliomas in vivo; (2) syndecan-1 is strongly expressed in the epithelial type of mesothelioma and in the epithelial component of biphasic mesotheliomas and the expression is reduced or lost in sarcomatoid differentiation; together with the finding that (3) syndecan-1 correlates with WT1 immuno-expression, this suggests that syndecan-1 might relate to the differentiation state of mesothelial/mesothelioma cells; and (4) syndecan-1-positive tumours are associated with a longer survival (p = 0.02) than mesotheliomas with no or little syndecan-1 expression, on univariate analysis.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/10550542&#34; target=&#34;_blank&#34;&gt;10550542&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Wilms’ tumour susceptibility gene 1 (WT1) is expressed during transitions of mesenchyme to epithelial tissues, as in the embryonic kidney, and it has been suggested as a marker for the mesothelial lineage. […] To investigate how the epithelial and fibroblast-like differentiation of benign mesothelial cells was correlated to WT1, PGs and hyaluronan synthase, we studied their expression by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) analyses. […] Cell lines with epithelial morphology expressed more mRNA coding for WT1 and cell surface PGs than did the fibroblastic ones, the difference being greatest for syndecan-4 and glypican. […] The increase in WT1-associated mRNA was about as great as that of syndecans. […] The results indicate that the regulation of mesothelial differentiation is multifactorial and also involves WT1 and several PGs.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/10757409&#34; target=&#34;_blank&#34;&gt;10757409&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, the immunoreactivity of thyroid transcription factor-1 (TTF-1), E-cadherin, BG8, WT1, and CD44S was investigated in 50 epithelial mesotheliomas, and 40 pulmonary and 95 nonpulmonary adenocarcinomas. […] Although WT1 immunostaining may also be useful, its value, as determined in this study, is lower than that reported by other investigators.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/11342772&#34; target=&#34;_blank&#34;&gt;11342772&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Wilms tumor protein-1 (WT1) was not detected in SS, but was present in 12 of 17 EMs. […] The discriminating features include extensive BerEp4 positivity, rarity of CD141, and lack of WT1 in SS.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/11954027&#34; target=&#34;_blank&#34;&gt;11954027&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has been shown that detection of the Wilms tumor susceptibility gene 1 protein (WT1) has diagnostic utility in the distinction of mesothelioma from adenocarcinoma in tissue sections of pleural tumors. […] This immunohistochemical study evaluates the effectiveness of WT1 as a marker for malignant mesothelioma in paraffin sections of cell block preparations derived from effusion specimens. […] The authors evaluated 111 cell blocks for WT1 immunoreactivity, including 14 mesotheliomas and 97 metastatic adenocarcinomas from various sites. […] Nuclear reactivity for WT1 was observed in all samples of mesothelioma. […] However, only 22 of 97 samples (23%) of metastatic adenocarcinoma, nearly all of which were of ovarian origin (91%), exhibited nuclear reactivity for WT1. […] In 14 other samples (most of pulmonary derivation), WT1 staining restricted to the cytoplasm was observed for some tumor cells and was regarded as nonspecific. […] Based on this staining profile, WT1 represents an effective marker for mesotheliomas in cell block preparations and can aid in its distinction from pulmonary adenocarcinoma. […] In assessment of effusion specimens with metastatic carcinoma, nuclear reactivity for WT1 is highly suggestive of an ovary primary tumor
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/12883236&#34; target=&#34;_blank&#34;&gt;12883236&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sixty epithelioid mesotheliomas and 50 lung adenocarcinomas were investigated for expression of the following markers: calretinin, cytokeratin 5/6, WT1, thrombomodulin, mesothelin, CD44S, HBME-1, N-cadherin, E-cadherin, MOC-31, thyroid transcription factor-1 (TTF-1), BG-8 (Lewisy), carcinoembryonic antigen (CEA), Ber-EP4, B72.3 (TAG-72), leu-M1 (CD15), CA19-9, epithelial membrane antigen (EMA), and vimentin. […] All (100%) of the mesotheliomas reacted for calretinin, cytokeratin 5/6, and mesothelin, 93% for WT1, 93% for EMA, 85% for HBME-1, 77% for thrombomodulin; 73% for CD44S, 73% for N-cadherin, 55% for vimentin, 40% for E-cadherin, 18% for Ber-EP4, 8% for MOC-31, 7% for BG-8, and none for CEA, B72.3, leu-M1, TTF-1, or CA19-9. […] Of the adenocarcinomas, 100% were positive for MOC-31, Ber-EP4, and EMA, 96% for BG-8, 88% for CEA, 88% for E-cadherin, 84% for B72.3, 74% for TTF-1, 72% for leu-M1, 68% for HBME-1, 48% for CD44S, 48% for CA19-9, 38% for mesothelin, 38% for vimentin, 30% for N-cadherin, 14% for thrombomodulin, 8% for calretinin, 2% for cytokeratin 5/6, and none for WT1. […] After analyzing the results, it is concluded that calretinin, cytokeratin 5/6, and WT1 are the best positive markers for differentiating epithelioid malignant mesothelioma from pulmonary adenocarcinoma. […] Because of their specificity and sensitivity for mesotheliomas, the best combination appears to be calretinin and cytokeratin 5/6 (or WT1) for the positive markers and CEA and MOC-31 (or B72.3, Ber-EP4, or BG-8) for the negative markers.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/15389250&#34; target=&#34;_blank&#34;&gt;15389250&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, immunohistochemistry using calretinin, cytokeratin 5/6, and WT1 was performed on all cases of mesothelioma, pulmonary adenocarcinoma, ovarian serous carcinoma, and renal cell carcinoma. […] Compared to other immunohistochemical markers of mesothelioma, D2-40 was as sensitive as calretinin and more sensitive than cytokeratin 5/6 and WT1.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/18181669&#34; target=&#34;_blank&#34;&gt;18181669&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A total of 72 formalin-fixed, paraffin-embedded cell block specimens from pleural and peritoneal effusions, including 5 mesotheliomas, 48 adenocarcinomas, and 19 benign effusions were stained with antibodies against calretinin, D2-40, XIAP, MOC-31, and WT1. […] WT1 was positive in 50% of benign effusions, 60% of mesotheliomas, and 27% of adenocarcinomas. […] WT1 proved to be nonspecific.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/18235409&#34; target=&#34;_blank&#34;&gt;18235409&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The molecular carcinogenesis of MPM is incompletely understood but alterations to genes NF2, c-met, WT1 RASSF and p16 have been described.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/20532500&#34; target=&#34;_blank&#34;&gt;20532500&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis. […] Using computer prediction analysis we designed analog peptides derived from WT1 sequences by substituting amino acids at key HLA-A0201 binding positions. […] We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1. […] Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells. […] Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response. […] This multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/21729925&#34; target=&#34;_blank&#34;&gt;21729925&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumors were characterized by mesothelin, calretinin, N-cadherin, D2-40 and Wilms tumor 1 (WT1) immunohistochemistry. […] Compared with the non-SP fraction (NSP), the SP fraction led to the development of tumors including cells with mesothelium precursor phenotype characterized by mesenchymal morphology, being WT1 negative but cytoplasmic D2-40 positive and having a tendency of increased tumorigenicity.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/22223868&#34; target=&#34;_blank&#34;&gt;22223868&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article describes several ongoing or recently completed phase II and III trials using novel agents vorinostat, everolimus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine, bevacizumab, cediranib, and thalidomide.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/22394205&#34; target=&#34;_blank&#34;&gt;22394205&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We further evaluated MTAP expression in a cohort of coagulated pleural effusions from 14 patients with MPM and 20 patients with RP by using a double-staining technique with Wilms tumour 1 (WT1) as a mesothelial marker.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/23428976&#34; target=&#34;_blank&#34;&gt;23428976&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both cell lines expressed tumor markers of mesothelioma such as mesothelin, podoplanin, WT1, calretinin and keratin 5/6 whereas they did not express either CEA or TTF-1 which are often used as markers of lung adenocarcinoma.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/24323466&#34; target=&#34;_blank&#34;&gt;24323466&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin and Wilms’ tumor gene (WT1) are mesothelial markers routinely used to confirm the diagnosis of malignant pleural mesothelioma (MPM). […] We investigated the prognostic value of calretinin and WT1 expression in predicting survival in a series of patients diagnosed with MPM in our institution. […] Calretinin and WT1 were stained for IHC analysis in formalin-fixed, paraffin-embedded sections and positivity was considered for tumors with &amp;gt;1 % of tumor cells stained. […] Calretinin IHC expression was positive in 83.7 % of patients and WT1 in 78.1 %. […] A significant association of calretinin and WT1 expression with epithelial histology was detected (p = 0.030 and p = 0.010). […] In the IHC markers analysis, we found a significant increase in OS for patients with WT1 positive expression (16.4 vs. […] In the multivariate analysis, epithelial histology and WT1 remained as significant prognostic factors for survival (p = 0.004 and p = 0.010, respectively). […] In our series of 52 MPM patients, epithelial histology, PS, NLR and WT1 expression are significant prognostic factors for survival. […] We concluded that WT1, but not calretinin, is a useful prognostic factor in MPM. […] The role of WT1 assessment is worth of prospective validation in future studies on MPM.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/24816068&#34; target=&#34;_blank&#34;&gt;24816068&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sixty epithelioid mesotheliomas and 80 breast carcinomas (40 triple negative and 40 estrogen receptor positive) were investigated for expression of the positive mesothelioma markers calretinin, keratin 5/6, mesothelin, podoplanin, thrombomodulin, and WT1; the positive carcinoma marker claudin 4; and the breast-associated markers gross cystic disease fluid protein 15 (GCDFP-15), mammaglobin, and GATA3. […] All of the epithelioid mesotheliomas reacted for calretinin and keratin 5/6, 93% for WT1; 88% for podoplanin; 77% for thrombomodulin; 23% for GATA3; and 0% for claudin 4, GCDFP-15, and mammaglobin, respectively. […] Of the triple-negative breast carcinomas, 100% expressed claudin 4; 5%, keratin 5/6; 30%, GATA3; 18%, mammaglobin; 15%, GCDFP-15; 56%, mesothelin; 38%, calretinin; 18%, thrombomodulin; 5%, WT1; and 3%, podoplanin. […] Among the estrogen receptor-positive breast carcinomas, 100% were claudin 4 and GATA3 positive; 70% expressed GCDFP-15; 63%, mammaglobin; 13%, calretinin; 13%, thrombomodulin; 8%, WT1; 5%, keratin 5/6; 3%, mesothelin; and 0%, podoplanin. […] It is concluded that podoplanin and WT1 are the best positive mesothelioma markers for differentiating epithelioid mesotheliomas from breast carcinomas.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/25044880&#34; target=&#34;_blank&#34;&gt;25044880&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although nuclear Wilms tumor 1 (WT1) expression is widely used to detect tumors of ovarian and mesothelial origin, it is less well known that WT1 is also expressed in the cytoplasm of melanomas and mesenchymal tumors. […] Because to the authors’ knowledge the diagnostic utility of cytoplasmic WT1 expression has not been explored to date, the usefulness of a WT1/AE1/AE3 dual-color immunostain in the workup of malignant effusions was evaluated. […] A total of 86 pleural effusions, including 17 metastatic melanomas, 31 metastatic adenocarcinomas, 10 malignant mesotheliomas, 10 lymphoproliferative disorders, 5 metastatic sarcomas, and 13 benign specimens, were immunostained using a peroxidase-based brown chromogen for WT1 and an alkaline phosphatase-based red chromogen for AE1/AE3 on cell block sections. […] The majority of malignant effusions stained in 1 of 4 distinctive patterns: 1) all lung and breast adenocarcinomas demonstrated cytoplasmic AE1/AE3 expression without nuclear or cytoplasmic WT1 expression; 2) serous carcinomas of Müllerian origin, mesotheliomas, and benign mesothelial cells were positive for cytoplasmic AE1/AE3 as well as nuclear WT1; 3) melanomas, sarcomas, and a subset of plasma cell neoplasms were positive for cytoplasmic expression of WT1 but negative for AE1/AE3; and 4) large B-cell lymphomas and a subset of plasma cell neoplasms were negative for both markers. […] A WT1/AE1/AE3 dual-color immunostain can reliably identify malignancy in pleural effusions and group malignant cells into discrete subsets, thereby narrowing the differential diagnosis.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/25208984&#34; target=&#34;_blank&#34;&gt;25208984&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The staining of calretinin (9/21) and WT1 (10/14) was generally weak and focal.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/25674287&#34; target=&#34;_blank&#34;&gt;25674287&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical staining shows that the tumor cells are positive for cytokeratin, CD31, Vimentin and WT1, and negative for CEA, TTF-1, Calretinin, Mesothelial Cell (MC), CD56, CK19, and Hepatocyte.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/25876971&#34; target=&#34;_blank&#34;&gt;25876971&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The expression levels of calretinin, Wilms’ tumor suppressor gene (WT1), podoplanin (D2-40), cytokeratins (CK5/6, AE1/AE3, and CAM5.2), epithelial membrane antigen, carcinoembryonic antigen, BerEP4, MOC31, thyroid transcription factor-1, estrogen receptor, and progesterone receptor in tumor tissues were measured using immunohistochemical staining by Japanese experts, and the pathological classification and diagnosis were made.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/26448888&#34; target=&#34;_blank&#34;&gt;26448888&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IHC studies showed the cells to be positive for calretinin, CK5/6, WT1, and CK7.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/27175358&#34; target=&#34;_blank&#34;&gt;27175358&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumour was positive for cytokeratin (AE1/AE3), calretinin, WT1 and mesothelin, confirming metastatic mesothelioma to the conjunctiva.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/27403364&#34; target=&#34;_blank&#34;&gt;27403364&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The epithelioid portion showed IHC reactivity for pan cytokeratin, CK5/6, D2-40, and calretinin and the small cell portion marked with CD99, pan cytokeratin, WT1, FLI1, S100, CD200, MyoD1, and CD15. […] Array based-comparative genomic hybridization (a-CGH) confirmed the tumor had numerous chromosome copy number losses, including 11p15.5-p11.12 and 22q12.1-q13.33, with loss of the EWSR1 and WT1 gene regions.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/28054314&#34; target=&#34;_blank&#34;&gt;28054314&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Wilms Tumor Protein 1 (WT1) is a transcription factor which is highly expressed by MPM and is involved in cellular development and survival. […] We evaluated the role of WT1 in two human MPM cell lines (MSTO and H2052) expressing high levels of WT1. […] We performed a knockdown of WT1 using siRNA. […] Knockdown of WT1 was confirmed by Westernblotting. […] After knockdown of WT1 we investigated the effect on proliferation, chemoresistance, chemotaxis and migration. […] We could demonstrate that knockdown of WT1 suppresses chemoresistance in both cell lines compared with control (scrambled siRNA). […] Additionally, WT1 knockdown reduces proliferation, chemotaxis and invasiveness of mesothelioma cell lines. […] WT1 reduces malignancy of malignant mesothelioma cell lines and might be a new molecular target in mesothelioma therapy. […] Further investigations are needed to discover the mechanisms of chemoresistance depending on WT1.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/28505004&#34; target=&#34;_blank&#34;&gt;28505004&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The fusion-positive cases displayed classic epithelioid morphology, immunoreactivity for cytokeratins and WT1, and negativity for S100.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/28810297&#34; target=&#34;_blank&#34;&gt;28810297&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor cells were imunohistochemically positive for cytokeratin (pan, 6/6), calretinin (5/6), podoplanin (6/6), D2-40 (4/6), vimentin (6/6), WT1 (4/6), CD10 (3/6), SMA (4/6), and variably positive for CK7, and CK8/18, but were negative for other linage-specific markers. […] 免疫组织化学结果显示，肿瘤细胞呈广谱细胞角蛋白(6/6)、calretinin (5/6)、podoplanin (6/6)、D2-40 (4/6)、波形蛋白(6/6)、WT1 (4/6)、CD10 (3/6)和平滑肌肌动蛋白(4/6)阳性，Ki-67阳性指数25%～55%，平均&amp;gt;40%，而其他标志物均阴性。
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/28972039&#34; target=&#34;_blank&#34;&gt;28972039&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Purpose:&lt;/b&gt; Determine the 1-year progression-free survival (PFS) rate among patients with malignant pleural mesothelioma (MPM) receiving the WT1 peptide vaccine galinpepimut-S after multimodality therapy versus those receiving control adjuvants.&lt;b&gt;Experimental Design:&lt;/b&gt; This double-blind, controlled, two center phase II trial randomized MPM patients after surgery and another treatment modality to galinpepimut-S with GM-CSF and Montanide or GM-CSF and Montanide alone.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29048219&#34; target=&#34;_blank&#34;&gt;29048219&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of immunohistochemistry markers performed were tabulated. - Immunohistochemistry markers positive in peritoneal mesothelioma in order of sensitivity were calretinin (244 of 244; 100%), WT1 (205 of 218; 94%), CK5/6 (173 of 194; 89%), mesothelin (132 of 150; 88%), and D2-40 (78 of 97; 80%).
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29050072&#34; target=&#34;_blank&#34;&gt;29050072&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A differential diagnosis antibody panel, including calretinin, WT1, CK5/6, D2-40, CAM5.2, CEA, TTF1, Napsin A, p63 and p40 was tested in all cases. &lt;b&gt;Results:&lt;/b&gt; All 80 cases of non-small cell lung cancer and 15 cases of carcinosarcoma were BAP1 positive. […] 同时所有病例均检测了常规用于间皮瘤鉴别诊断的抗体组合，包括calretinin、WT1、细胞角蛋白5/6、D2－40、CAM5.2、癌胚抗原、甲状腺转录因子1、Napsin A、p63和p40。
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29100432&#34; target=&#34;_blank&#34;&gt;29100432&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To develop cancer antigen-targeted immunotherapeutic strategies for malignant pleural mesothelioma (MPM), we investigated the individual and coexpressions of the cancer-associated antigens mesothelin (MSLN), cancer antigen 125 (CA125), and Wilms tumor 1 (WT1) in both epithelioid and non-epithelioid MPM. […] Positive expression of MSLN, CA125, and WT1 were demonstrated in 93%, 75%, and 97% of epithelioid MPM cases, and 57%, 33%, and 98% of non-epithelioid MPM cases, respectively. […] More than two-thirds of MPM cases had ≥50% distribution of MSLN-positive cells and, among the remaining third, half had ≥50% distribution of WT1-positive cells.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29757709&#34; target=&#34;_blank&#34;&gt;29757709&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Many antibodies with a positive diagnostic value including claretinin, mesothelin, WT1 and antibodies with a negative diagnostic value including TTF1, EMA, CD15 are recommended by the scientific societies.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29873855&#34; target=&#34;_blank&#34;&gt;29873855&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry for calretinin, CK5/6, WT1, CK7 and TTF1 was used on CB sections to confirm the cytological diagnosis of MM.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30113886&#34; target=&#34;_blank&#34;&gt;30113886&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The odds of carrying a mutation in BAP1 (OR, 1,658; 95% CI, 199 to 76,224; P &amp;lt; .001), BRCA2 (OR, 5; 95% CI, 1.0 to 14.7; P = .03), CDKN2A (OR, 53; 95% CI, 6 to 249; P &amp;lt; .001), TMEM127 (OR, 88; 95% CI, 1.7 to 1,105; P = .01), VHL (OR, 51; 95% CI, 1.1 to 453; P = .02), and WT1 (OR, 20; 95% CI, 0.5 to 135; P = .049) were significantly higher in MM cases than in a noncancer control population.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30156768&#34; target=&#34;_blank&#34;&gt;30156768&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differentiation of reactive mesothelial cells from malignant mesothelioma and adenocarcinoma is a recurring theme, and Wilms tumor 1 (WT1)/AE1/AE3, claudin 4, and BRCA1-associated protein 1 (BAP1) immunostains are useful new tools in the armamentarium.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30450291&#34; target=&#34;_blank&#34;&gt;30450291&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most sensitive immunohistochemical markers are calretinin (100%), WT1 (94%) and CK5/6 (89%).
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30512336&#34; target=&#34;_blank&#34;&gt;30512336&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular carcinogenesis of MPM is incompletely understood, but involves NF2, WT1 RASSF1, p16 gene alterations and the more recently described BAP-1. […] La carcinogenèse moléculaire implique les gènes NF2, WT1, RASSF1, p16 et BAP- 1, qui régulent l’apoptose, l’invasion et la motilité cellulaire, le contrôle de la division cellulaire et de la réparation de l’ADN.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30604735&#34; target=&#34;_blank&#34;&gt;30604735&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among the mesothelial markers, WT1 was positive in 17 of 20 (85%) cases and calretinin was positive in 20 of 21 (95.23%) cases.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30927189&#34; target=&#34;_blank&#34;&gt;30927189&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An immunohistochemical panel of calretinin, WT1, BEREP4, MOC31, and TTF1 confirmed the diagnosis of primary lung adenocarcinoma.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/30937282&#34; target=&#34;_blank&#34;&gt;30937282&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biopsy demonstrated positive staining with AE1/3, CK7, CK5/6, WT1, calretinin and D2 40.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/32074730&#34; target=&#34;_blank&#34;&gt;32074730&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical staining for calretinin, cytokeratin 5/6, WT1 and Ki-67 were positive. […] 免疫组织化学示Calretinin、细胞角蛋白（CK）5/6、WT1、Ki-67阳性。
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/7856747&#34; target=&#34;_blank&#34;&gt;7856747&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of evidence suggesting that the Wilms’ tumor susceptibility gene (WT1), unlike other tumor suppressor genes, is restricted mostly to mesenchymally derived tissues, we hypothesized that the WT1 gene products could serve as a potential marker for mesothelioma. […] The expression of WT1 mRNA was analyzed in 19 malignant mesothelioma cell lines and 9 tumors and compared with the expression of WT1 in 10 non-small cell lung cancer lines and 9 lung cancer specimens. […] WT1 mRNA was detectable by Northern analysis in 16 of 19 mesothelioma cell lines and in 5 of 8 malignant mesothelioma tumors. […] In contrast, WT1 mRNA was not detected by Northern analysis in non-small cell lung cancer lines or carcinomas. […] Immunoprecipitation with an anti-WT1 monoclonal antibody showed that a 52- to 54-kd protein was present in 4 mesothelioma cell lines. […] Immunostaining with this antibody localized the WT1 protein to the nucleus in two mesothelioma lines and in 20 of 21 mesothelioma tumors examined. […] The detection of WT1 mRNA or protein may thus provide a specific molecular or immunohistochemical marker for differentiation of mesothelioma from other pleural tumors, in particular, adenocarcinoma.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/9072005&#34; target=&#34;_blank&#34;&gt;9072005&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Wilms tumour 1 (WT1) gene is believed to contribute to the growth and differentiation of certain tissues, including mesothelium. […] This study assessed WT1 gene status by mutational screening in 42 malignant mesotheliomas (MMs) and 3 MM cell lines and detected two tumours with identical heterozygous single nucleotide deletions in intron 7, with no apparent consequence for WT1 function. […] Furthermore, the expression pattern of the WT1 gene was studied in MMs and related lesions using three anti-WT1 monoclonal antibodies (MAbs). […] WT1 immunoreactivity was absent in all primary tumours of lung and in pleural metastases from adenocarcinomas of breast and colon; immunoreactivity was present in pleural metastases from renal carcinomas, melanomas, and papillary carcinomas of the ovary. […] Expression of the WT1 protein in MM was not correlated with survival. […] Coordinate expression of the WT1 protein and its putative transcriptional target genes was determined by correlating WT1 immunostaining with epidermal growth factor receptor (EGF-R) and insulin-like growth factor 1 receptor (IGF-1R) expression on MM and NNM; no significant correlation was found, irrespective of p53 expression status. […] Finally, the putative involvement of WT1 in cell-type transition was supported by this study, in that epithelial mesothelioma showed the strongest WT1 immunoreactivity while sarcomatous mesothelioma showed the least.
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>WT1</title>
      <link>/mesothelioma/genepanel/7490/clinvar/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/7490/clinvar/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;WT1 transcription factor&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;clinvar-summary&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;ClinVar Summary&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:16px&#34; align=&#34;center&#34;&gt;
Under development
&lt;/p&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>WT1</title>
      <link>/mesothelioma/genepanel/7490/geo/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/7490/geo/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;WT1 transcription factor&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;geo-dataset-summary&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;GEO dataset Summary&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:16px&#34; align=&#34;center&#34;&gt;
Under development
&lt;/p&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
